GLP-1 and Amylin in the Treatment of Obesity

Curr Diab Rep. 2016 Jan;16(1):1. doi: 10.1007/s11892-015-0693-3.


For decades, extensive research has aimed to clarify the role of pancreas and gut-derived peptide hormones in the regulation of glucose homeostasis and feeding behavior. Among these are the beta-cell hormone amylin and the intestinal L cell hormone glucagon-like peptide-1 (GLP-1). They exhibit distinct and yet several similar physiological actions including suppression of food intake, postprandial glucagon secretion, and gastric emptying-altogether lowering plasma glucose and body weight. These actions have been clinically exploited by the development of amylin and GLP-1 hormone analogs now used for treatment of diabetes and obesity. This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.

Keywords: Amylin; Dual agonist; GLP-1; Obesity treatment; Phybrid.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus / drug therapy
  • Eating
  • Glucagon-Like Peptide 1 / analogs & derivatives
  • Glucagon-Like Peptide 1 / therapeutic use*
  • Humans
  • Insulin-Secreting Cells / drug effects
  • Islet Amyloid Polypeptide / chemistry
  • Islet Amyloid Polypeptide / therapeutic use*
  • Obesity / drug therapy*


  • Islet Amyloid Polypeptide
  • Glucagon-Like Peptide 1